ARMP News & Events

Reports Q1 revenue $0.8M vs. $0.5M last year. "Our top priority in 2026 is advancing Armata's lead Staphylococcus aureus therapeutic phage candidate, AP-SA02, into a Phase 3 superiority study in complicated S. aureus bacteremia," said CEO Deborah Birx. "We are focused on initiating a rigorously designed and operationally efficient study designed to support a future Biologics License Application submission and potential registration. If successful, AP-SA02 has the potential to offer an important new treatment option for patients facing this serious and often life-threatening infection...I also want to highlight other important recent developments including the granting by the FDA of both Qualified Infectious Disease Product and Fast Track Designation for AP-SA02...We are pleased to have the ongoing backing of Innoviva, our largest shareholder who has supported us since 2020, in providing additional financing that will help us to advance AP-SA02, and we are continuing to pursue additional sources of funding, including non-dilutive sources".

Armata Pharmaceuticals announced that the U.S. FDA has granted Fast Track Designation to AP-SA02, the company's intravenously administered Staphylococcus aureus multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin resistant S. aureus.

The company recognized grant revenue of $1.1M for the three months ended December 31, 2025 as compared to $1.2M in the comparable period in 2024, which represents MTEC's share of the costs incurred for the company's AP-SA02 program for the treatment of Staphylococcus aureus bacteremia.